CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. In particular, we are focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Source
No articles found.
Sage Therapeutics is a biopharmaceutical company committed to developing novel the...
Sage Therapeutics is a biopharmaceutical compan...
Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disor...
Rhythm is a biopharmaceutical company dedicated...
LeMaitre Vascular is a leading global innovator, manufacturer and marketer of devi...
LeMaitre Vascular is a leading global innovator...
Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission...
Teligent is a specialty generic pharmaceutical ...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...
Molecular Templates is focused on the discovery, development, and commercializatio...
Molecular Templates is focused on the discovery...
Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...
Headquartered in New York, BeyondSpring Inc. (B...
Join the National Investor Network and get the latest information with your interests in mind.